Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Brighton Jones LLC

Brighton Jones LLC lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,158 shares of the medical equipment provider’s stock after selling 156 shares during the quarter. Brighton Jones LLC’s holdings in Intuitive Surgical were worth $4,074,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Capital Research Global Investors acquired a new stake in Intuitive Surgical during the first quarter valued at $374,390,000. Coatue Management LLC grew its position in Intuitive Surgical by 65.7% during the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after buying an additional 516,054 shares during the period. Vanguard Group Inc. grew its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the period. Edgewood Management LLC grew its position in Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after buying an additional 302,382 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on ISRG shares. Barclays lifted their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Morgan Stanley lifted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Piper Sandler lifted their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Up 1.6 %

ISRG opened at $490.01 on Friday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.18. The business has a fifty day simple moving average of $467.17 and a 200-day simple moving average of $424.26. The firm has a market cap of $173.81 billion, a P/E ratio of 88.45, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the business posted $1.18 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. Sell-side analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In related news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares in the company, valued at $402,519.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now directly owns 821 shares of the company’s stock, valued at $402,519.88. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 over the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.